Bryan Helwig, Ph.D. is an associate with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Helwig has a wide range of experience in drafting and prosecuting patent applications in pharmaceutical, biology, biochemistry, and life sciences. In addition to U.S. prosecution Dr. Helwig is versed in prosecution of international applications. He advises on novel and emerging drug and biologic protection. Further, Dr. Helwig advises clients on freedom to operate, patent infringement, and patent validity as well as litigation and litigation-related issues.
Prior to joining MBHB, Dr. Helwig directed a research laboratory for the U.S. Department of Defense. His research portfolio was tasked with developing pharmaceutical and non-pharmaceutical therapies, as well as advancement of molecular and physiological device technologies, that aid Warfighter survival in extreme environments. The integrative research utilized a wide range of molecular biology, protein chemistry and high throughput technologies. In addition, Dr. Helwig has also served as a consultant to multiple Fortune 500 companies advising on scientific validity of labeling claims and product development.
Dr. Helwig’s graduate and post-doctoral work focused on transformation of stem cells into neuron and cardiac cells, heart failure, and alterations in central nervous control of autonomic function.